

CLAIMS

1. An inhibitor of lymphocyte activation comprising, as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1.
- 5 2. An inhibitor according to claim 1 in which the lymphocytes are T cells.
3. An inhibitor according to claim 1 in which the lymphocytes are B cells.
- 10 4. An inhibitor according to any of claims 1 to 3 in which the antibody is a monoclonal antibody.
5. An inhibitor according to claim 4 in which the antibody has the constant region of human antibody.
- 15 6. An inhibitor according to claim 4 or 5 in which the antibody is a chimeric antibody or a humanized antibody.
7. An inhibitor according to claim 4 in which the antibody is anti-HM1.24 antibody.
- 20 8. An inhibitor according to claim 6 in which the antibody is chimeric anti-HM1.24 antibody.
9. An inhibitor according to claim 6 in which the antibody is humanized anti-HM1.24 antibody.
- 25 10. An inhibitor according to claim 1 in which the antibody specifically binds to an epitope recognized by anti-HM1.24 antibody.
11. A preventive and/or therapeutic agent for diseases associated with lymphocyte activation, comprising, as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1.
- 30 12. The preventive and/or therapeutic agent according to claim 11, in which the disease associated with lymphocyte activation is an autoimmune disease, a rejection in organ transplantation, or allergy.